Smoking May Not Inhibit Response to Rituximab in Rheumatoid Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - March 17, 2019 Category: Orthopaedics Tags: Perspective Source Type: news

European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease
Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes. (Source: Roche Media News)
Source: Roche Media News - March 15, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease
Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - March 15, 2019 Category: Pharmaceuticals Source Type: news

Drug Combo Granted Priority Review for Untreated Follicular Lymphoma
The FDA has granted Priority Review to Celgene ’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

B-cell Depletion in Nephrotic Syndrome: Latest on Rituximab B-cell Depletion in Nephrotic Syndrome: Latest on Rituximab
Dr Desai shares his views on a recent study examining the efficacy of rituximab in treating patients with relapsing, steroid-dependent, and steroid-resistant nephrotic syndrome.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2019 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Ofatumumab Shows Limited Activity in Previously Untreated Follicular Lymphoma
In this study, single-agent ofatumumab did not show superiority to rituximab or obinutuzumab, raising the question of whether ofatumumab should have a role in the treatment of follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Build Biologics Not Barriers
iBio ’s unique partnership with Beijing’s CC-Pharming will bring economical, plant-derived rituximab to China (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 19, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (Source: Roche Media News)
Source: Roche Media News - February 19, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (Source: Roche Investor Update)
Source: Roche Investor Update - February 19, 2019 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokine...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

The MBDA Score Tracks Response to Rituximab Treatment in RA The MBDA Score Tracks Response to Rituximab Treatment in RA
Are changes in the MBDA score indicative of rituximab treatment efficacy in patients with rheumatoid arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

New treatment for adults with chronic lymphocytic leukaemia
NICE is recommending venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia. Thousands of patients should benefit, NICE says. (Source: NHS Networks)
Source: NHS Networks - January 23, 2019 Category: UK Health Source Type: news

Maintenance Rituximab Post Bendamustine/Rituximab in FL
Is the continuation of maintenance rituximab beneficial post bendamustine plus rituximab treatment in FL Patients? (Source: CancerNetwork)
Source: CancerNetwork - January 22, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Drug May Delay MS Disability for Some
A new Swiss study found that people who have secondary progressive MS who took the drug rituximab reported less disabling symptoms over a 10-year period than those who didn't. People taking the drug also had a slower progression of MS symptoms. (Source: WebMD Health)
Source: WebMD Health - January 9, 2019 Category: Consumer Health News Source Type: news

Rituximab (Rituxan) May Delay MS Disability for Some
WEDNESDAY, Jan. 9, 2019 -- An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds. The medication is called rituximab (Rituxan). It's used to treat a number... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 9, 2019 Category: General Medicine Source Type: news

Rituximab Beneficial in Secondary Progressive MS
MONDAY, Jan. 7, 2019 -- For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 7, 2019 Category: Pharmaceuticals Source Type: news

Autoimmune Sequelae Following Rituximab Therapy Autoimmune Sequelae Following Rituximab Therapy
A new review provides insight into the mechanisms involved in the development of new autoimmune disease among patients receiving rituximab treatment.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 26, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Lymphoma Still Top COD in Patients During Rituximab Era
Despite improved outcomes seen in the rituximab era, the leading cause of death in patients with follicular lymphoma during the first decade remains lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Another Rituximab Biosimilar Passes Lymphoma Test
(MedPage Today) -- Noninferior to EU-licensed agent in randomized trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 6, 2018 Category: Hematology Source Type: news

Truxima (Rituximab-abbs Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2018 Category: Drugs & Pharmacology Source Type: news

AbbVie Presents New Data from Phase 3 MURANO Trial of ...
- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1] - Of the 130 patients who completed rituximab plus the 24-month fixed duration of venetoclax and remained off therapy for a median of 9.9 months, the estimated PFS rate at six and 12 months were 92 percent and 87 percent, respectively[1] -...This story is related to the following:Pharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - December 5, 2018 Category: Medical Devices Source Type: news

Ibrutinib and Rituximab for Untreated CLL:'Practice Changing'Ibrutinib and Rituximab for Untreated CLL:'Practice Changing '
The combination of ibrutinib and rituximab trumps the current gold standard chemoimmunotherapy of FCR in young, fit patients with untreated CLL in a large NCI trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2018 Category: American Health Source Type: news

Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib Alone for Older Patients With Untreated CLL
Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine – rituximab combination for older patients with chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Four Cycles of CHOP Instead of Six for Favorable DLBCL Four Cycles of CHOP Instead of Six for Favorable DLBCL
Patients with favorable-prognosis DLBCL receiving four cycles of R-CHOP followed by two additional cycles of rituximab had outcomes similar to those in patients receiving six cycles.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ibrutinib Alone Wins in Older CLL Patients
(MedPage Today) -- Adding rituximab offered no added benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 1, 2018 Category: Hematology Source Type: news

Monthly News Roundup - November 2018
FDA Approves Truxima as the First Biosimilar to Rituxan In November, the U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) injection from Celltrion as the first biosimilar to Rituxan (rituximab) for the treatment of adult... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2018 Category: Pharmaceuticals Source Type: news

Outcomes and PFS at 24 Months for Patients With DLBCL Outcomes and PFS at 24 Months for Patients With DLBCL
The potential for positive survival outcomes is excellent in patients with DLBCL who have not progressed 24 months after receiving rituximab-containing immunochemotherapy.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA approves first biosimilar to Roche cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

First Biosimilar Rituximab for Lymphoma Approved in US First Biosimilar Rituximab for Lymphoma Approved in US
Truxima, designed for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma, can be used as a single agent or in combination with chemotherapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Rituximab Biosimilar for NHL
(MedPage Today) -- Indications for front line or beyond, single agent or combination (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 28, 2018 Category: American Health Source Type: news

FDA approves first biosimilar to Roche's cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin ’s Lymphoma
November 28, 2018 -- The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

U.S. FDA approves first biosimilar to Roche's cancer drug Rituxan
The U.S. Food and Drug Administration on Wednesday approved Celltrion Inc's Truxima, making it the first biosimilar to Roche Holding AG's Rituxan available in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said today. Truxima, as with Rituxan, is approved to treat... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’ s lymphoma
The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’ s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’s lymphoma
The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday. A biosimilar is a biological product that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 28, 2018 Category: General Medicine Source Type: news

Rituximab for Nephrotic Syndrome in Kids: A Note of Caution Rituximab for Nephrotic Syndrome in Kids: A Note of Caution
Dr William Basco hesitates to recommend an immediate switch to rituximab as a steroid-sparing agent in children with nephrotic syndrome.Medscape Pediatrics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 27, 2018 Category: Consumer Health News Tags: Pediatrics Viewpoint Source Type: news

Efficacy of Rituximab Biosimilar in Follicular Lymphoma
A phase III study looks at the efficacy and safety of rituximab biosimilar CT-P10 in patients with follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Rituximab Promising in Childhood Vasculitis
(MedPage Today) -- Treatment was steroid-sparing in Hemoch-Schonlein purpura (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 15, 2018 Category: Pediatrics Source Type: news

Sandoz abandons Rituxan biosim in U.S.
Sandoz announced that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 9, 2018 Category: Pharmaceuticals Source Type: news

Hypogammaglobulinemia Screening Needed for Patients Receiving Rituximab Hypogammaglobulinemia Screening Needed for Patients Receiving Rituximab
Patients being considered for rituximab therapy should be screened for hypogammaglobulinemia before and after rituximab administration, researchers report.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 8, 2018 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Treating Advanced Indolent Follicular Lymphoma Without Chemotherapy
New research evaluated whether symptomatic indolent follicular lymphoma requires new long-term therapy after first-line rituximab without chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Novartis scraps U.S. filing for biosimilar rituximab
Novartis International AG ’s Sandoz division will abandon its quest to win U.S. approval for rituximab. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2018 Category: Pharmaceuticals Source Type: news

Novartis abandons effort for U.S. approval of biosimilar rituximab
Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news